Press Releases April 23, 2026 04:01 PM

TTM Technologies to Host 2026 Investor Day on May 27, 2026

TTM Technologies Announces 2026 Investor Day Event at Nasdaq to Discuss Business Outlook and Future Opportunities

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
TTMI

TTM Technologies, a leading global manufacturer of technology products such as RF components and printed circuit boards, announced its 2026 Investor Day to be held on May 27, 2026, at the Nasdaq Exchange in New York City. The event will feature presentations and Q&A with executive leadership and will be webcast live.

TTM Technologies to Host 2026 Investor Day on May 27, 2026
TTMI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • TTM Technologies is hosting an Investor Day to share business updates and future opportunities with investors.
  • The event will take place at the Nasdaq Exchange and include live presentations and a Q&A session with top executives.
  • As a global manufacturer of advanced technology products including PCBs and RF components, TTM’s operations impact the technology manufacturing sector.

SANTA ANA, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- TTM Technologies, Inc. (NASDAQ: TTMI), a leading global manufacturer of technology products, including mission systems, radio frequency (“RF”) components and RF microwave/microelectronic assemblies, and technologically advanced interconnect solutions, including printed circuit boards (“PCBs”) and substrates, today announced plans to discuss its business and future opportunities at its 2026 Investor Day on Wednesday, May 27, 2026 at the Nasdaq Exchange in New York City. The event will feature presentations, as well as a question-and-answer session with members of the Company’s executive leadership team, including Edwin Roks, President, Chief Executive Officer and Board member, and Dan Boehle, Executive Vice President and Chief Financial Officer.

Due to limited capacity, in-person attendance is by invitation only. The live webcast of the event is scheduled to begin at approximately 8:30 a.m. ET and is expected to conclude at approximately 12:15 p.m. ET. All interested parties are invited to access the webcast through the following registration link: TTM Technologies, Inc. 2026 Investor Day.

A replay of the webcast and slides shown during the presentations will also be available on the Company’s website following the event.

About TTM

TTM Technologies, Inc. is a leading global manufacturer of technology products, including mission systems, radio frequency (“RF”) components, RF microwave/microelectronic assemblies, and technologically advanced interconnect products, including printed circuit boards (“PCBs”) and substrates. TTM stands for time-to-market, representing how TTM's time-critical, one-stop design, engineering and manufacturing services enable customers to reduce the time required to develop new products and bring them to market. Additional information can be found at www.ttm.com.

Contact:

Sean K.F. Hannan,
Vice President, Investor Relations
TTM Technologies, Inc.
sean.hannan@ttmtech.com
+1 339 466 7737

Winnie Ng
Vice President, Corporate Marketing
TTM Technologies, Inc.
winnie.ng@ttm.com
+852 2660 4287 / +1 714 327 3000


Risks

  • Event attendance is limited to invite-only in-person with a webcast, which may limit investor engagement.
  • Market reaction to new strategic updates or financial disclosures at the event is uncertain.
  • The company's future growth prospects depend on ongoing demand in the technology and electronics manufacturing sectors, which can be affected by broader economic and supply chain conditions.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026